Đăng xuất
Pharmacological group: Drugs for the treatment of gout. ATC Code: M04AC01.
Pharmacology: Pharmacodynamics: The exact mechanism of action of colchicine in gout has not been confirmed. It is associated with inhibition of leukocyte migration; reduction of lactic acid production by leukocytes leading to decreased uric acid formation; interference with the formation of kinin and phagocytopenia due to reduced inflammatory responses.
Colchicine exerts its effects by reducing the inflammatory response to the deposited crystals and reducing phagocytosis.
Colchicine reduces the production of lactic acid directly by leukocytes and indirectly by reducing phagocytosis, thereby disrupting the cycle of urate crystal deposition and the inflammatory response that sustains the acute attack.
The oxidation of glucose in white blood cells during phagocytic as well as non-phagocytosis is prevented by colchicine.
Colchicine is not an analgesic even if it does relieve acute pain. Colchicine is not a drug that increases uric acid elimination, so it will not prevent the progression of gout to chronic gout arthritis. Colchicine has a prophylactic and preventive effect, helping to reduce the frequency of exacerbations, relieve frequent pain and reduce discomfort for patients.
Colchicine may cause temporary leukopenia, followed by leukocytosis.
Pharmacokinetics: Children: There are no pharmacokinetic data in children.
Absorption: Colchicine is readily absorbed after oral administration, reaching peak plasma concentrations within 2 hours.
The plasma half-life is approximately 1 hour, 60 hours in leucocytes, which is increased in the renal impairment and decreased in hepatic function impairment.
Distribution: Colchicine is distributed into leukocytes, liver, spleen, and kidneys and undergoes enterohepatic circulation.
Metabolism: Colchicine is deacetylated in the liver.
Elimination: Colchicine is primarily excreted through feces, with 10-20% in the urine. The proportion excreted in the urine increases in patients with liver disease.
